Insilico Medicine to Present Phase 1 ISM6331 Results at ESMO 2026

Insilico Medicine has announced that first-in-human Phase 1 data for ISM6331, an AI-designed pan-TEAD inhibitor, has been accepted for a Rapid Oral presentation at the 2026 ESMO Congress in Madrid. The update positions ISM6331 as a potential new small-molecule approach to modulating the Hippo pathway, a signaling axis frequently implicated in aggressive solid tumors and therapy resistance. The presentation is scheduled for Sunday, October 25, 2026, under abstract #997.

TEAD transcription factors act as the principal downstream mediators of Hippo signaling. In many cancers, dysregulated Hippo-TEAD activity drives cell proliferation, survival programs, and maladaptive tissue growth. Although the TEAD node has been widely viewed as a compelling target, historically, creating selective, drug-like small molecules that effectively inhibit TEAD has been difficult from a medicinal chemistry perspective.

ISM6331 is designed to inhibit TEAD activity using Insilico Medicine’s generative AI-powered discovery platform, Chemistry42. The company describes the compound as a novel and potent pan-TEAD inhibitor, with the goal of achieving selective suppression of pan-TEAD transcriptional signaling. This focus on the TEAD transcription machinery reflects a broader shift in oncology drug development toward pathway-level control rather than single-protein inhibition.

The study being presented is a global, multicenter Phase 1 trial enrolling patients with mesothelioma and other advanced solid tumors. Investigators are evaluating safety and tolerability, along with pharmacokinetics, to characterize exposure and dose behavior. In parallel, the trial includes preliminary assessments of antitumor activity to inform future expansion cohorts and development decisions.

For oncology patients with limited options—particularly in hard-to-treat indications such as malignant mesothelioma—early clinical signals can carry high relevance. Insilico’s leadership emphasized that the selection of ISM6331 for a Rapid Oral slot reflects confidence in the early translational value of the program.

Beyond the molecule itself, the announcement underscores Insilico’s broader strategy: connecting biology, chemistry, and clinical trial outcome prediction through modern machine learning systems. The company frames Chemistry42 as a key component of an end-to-end generative workflow, including target-inspired design and optimization.

If the Phase 1 results demonstrate acceptable safety and meaningful biological activity, ISM6331 could extend TEAD inhibition from preclinical promise into clinical validation. The ESMO Rapid Oral format also suggests that the dataset may include timely, decision-relevant findings for the field.

In summary, ISM6331’s ESMO 2026 Rapid Oral acceptance spotlights a TEAD-centered Hippo pathway program built with generative AI and moving into clinical interpretation. The upcoming presentation will be closely watched by researchers seeking actionable evidence that AI-guided small-molecule design can overcome longstanding constraints in TEAD inhibitor development.